Added to YB: 2026-09-08
Pitch date: 2026-09-05
PHVS [bullish]
Pharvaris N.V.
Author Info
Molecule -> Market is a financial analyst specializing in pharmaceutical and biotechnology companies. I publish detailed research on biotech stocks, using DCF modeling, clinical trial analysis, and market positioning data. Sign up for the newsletter.
Company Info
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Market Cap
$2.1B
Pitch Price
N/A
Price Target
58.01
Dividend
N/A
EV/EBITDA
-9.96
P/E
-11.57
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Pharvaris: CHAPTER-3 Data Lands This Quarter And The Setup Is Favorable
PHVS: Pharvaris offers a binary Q3 2026 setup around CHAPTER-3, with an estimated 80% success probability for once-daily prophylactic deucrictibant based on an 84.5% placebo-adjusted Phase 2 attack-rate reduction and positive Phase 3 on-demand data. The model yields $50.08 on success and $58.01 after subsequent on-demand approval, versus $13.36 on failure. Key risks are the ~85-patient trial, efficacy regression and XR trough coverage.
Read full article (9 min)